Hanmi Pharm Co Ltd (128940) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩42.02 Billion ≈ $28.48 Million USD) by net assets (₩1.35 Trillion ≈ $911.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 128940 stock market capitalisation for the company's overall valuation and market capitalisation.
Hanmi Pharm Co Ltd - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Hanmi Pharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hanmi Pharm Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hanmi Pharm Co Ltd ranked by their cash flow conversion efficiency. Explore Hanmi Pharm Co Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Texas Capital Bancshares, Inc.
NASDAQ:TCBI
|
0.024x |
|
LG Uplus
KO:032640
|
0.095x |
|
Sydbank A/S
CO:SYDB
|
-0.099x |
|
ENSTAR GROUP LTD DL-01
F:48R
|
N/A |
|
All Winner Technology Co Ltd
SHE:300458
|
0.041x |
|
Jiangxi Zhengbang Technology Co Ltd
SHE:002157
|
0.025x |
|
VisEra Technologies Co. Ltd.
TW:6789
|
0.038x |
|
Companhia de Saneamento de Minas Gerais
SA:CSMG3
|
0.057x |
Annual Cash Flow Conversion Efficiency for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual cash flow conversion efficiency of Hanmi Pharm Co Ltd from 2010 to 2024. View Hanmi Pharm Co Ltd (128940) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩1.24 Trillion ≈ $840.84 Million |
₩193.49 Billion ≈ $131.12 Million |
0.156x | -20.77% |
| 2023-12-31 | ₩1.10 Trillion ≈ $745.60 Million |
₩216.54 Billion ≈ $146.74 Million |
0.197x | +22.41% |
| 2022-12-31 | ₩1.01 Trillion ≈ $683.94 Million |
₩162.27 Billion ≈ $109.97 Million |
0.161x | -26.09% |
| 2021-12-31 | ₩928.26 Billion ≈ $629.07 Million |
₩201.92 Billion ≈ $136.84 Million |
0.218x | +19.42% |
| 2020-12-31 | ₩831.89 Billion ≈ $563.76 Million |
₩151.53 Billion ≈ $102.69 Million |
0.182x | +1103.39% |
| 2019-12-31 | ₩822.26 Billion ≈ $557.23 Million |
₩12.45 Billion ≈ $8.43 Million |
0.015x | -54.02% |
| 2018-12-31 | ₩789.26 Billion ≈ $534.87 Million |
₩25.98 Billion ≈ $17.61 Million |
0.033x | +141.47% |
| 2017-12-31 | ₩792.42 Billion ≈ $537.01 Million |
₩-62.91 Billion ≈ $-42.63 Million |
-0.079x | -114.12% |
| 2016-12-31 | ₩734.52 Billion ≈ $497.77 Million |
₩412.97 Billion ≈ $279.86 Million |
0.562x | +311.70% |
| 2015-12-31 | ₩744.81 Billion ≈ $504.75 Million |
₩101.71 Billion ≈ $68.93 Million |
0.137x | +345.18% |
| 2014-12-31 | ₩589.25 Billion ≈ $399.32 Million |
₩-32.82 Billion ≈ $-22.24 Million |
-0.056x | -129.98% |
| 2013-12-31 | ₩462.92 Billion ≈ $313.71 Million |
₩85.99 Billion ≈ $58.28 Million |
0.186x | +20.19% |
| 2012-12-31 | ₩409.34 Billion ≈ $277.41 Million |
₩63.27 Billion ≈ $42.88 Million |
0.155x | -4.64% |
| 2011-12-31 | ₩378.22 Billion ≈ $256.32 Million |
₩61.30 Billion ≈ $41.54 Million |
0.162x | +178.39% |
| 2010-12-31 | ₩325.38 Billion ≈ $220.50 Million |
₩18.94 Billion ≈ $12.84 Million |
0.058x | -- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more